Justin Meuse, MD
Neurology · Austin, TXNPI 1518100742
Payments from drug & device makers
Across 228 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- AbbVie$517
- UCB, Inc.$236
- SK Life Science, Inc.$194
- Amgen$148
- Biohaven Pharmaceuticals, Inc.$147
- plus $994 from 26 others
What the payments were for
- Food & beverage$4,050100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 90 | $1,826 |
| AbbVie(2 entities) | 30 | $517 |
| UCB, Inc. | 16 | $236 |
| SK Life Science, Inc. | 23 | $194 |
| Amgen | 7 | $148 |
| Biohaven Pharmaceuticals, Inc. | 8 | $147 |
| Biogen | 8 | $142 |
| Novartis | 5 | $97 |
| EMD Serono, Inc. | 4 | $73 |
| Sanofi | 3 | $71 |
| Lilly USA, LLC | 4 | $64 |
| Eisai Inc. | 3 | $53 |
| Jazz Pharmaceuticals Inc. | 3 | $50 |
| Bristol Myers Squibb | 2 | $49 |
| Alnylam Pharmaceuticals Inc. | 3 | $46 |
| Acadia Pharmaceuticals Inc | 2 | $40 |
| Amneal Pharmaceuticals LLC | 2 | $31 |
| Merz Pharmaceuticals, LLC | 1 | $29 |
| ANI Pharmaceuticals, Inc. | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Livanova USA, Inc. | 1 | $24 |
| Upsher-smith Laboratories LLC | 1 | $21 |
| Neuropace, Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| GE HealthCare | 1 | $18 |
| C2n Diagnostics, LLC | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Tanabe Pharma America, Inc. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Lundbeck LLC | 1 | $13 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
| Abbott | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,062 in reported general payments places this provider in the 50th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 252 | $307,598 |
| EpidiolexCannabidiol (Cbd) | 57 | $253,220 |
| NuplazidPimavanserin Tartrate | 19 | $93,893 |
| BriviactBrivaracetam | 55 | $91,848 |
| IngrezzaValbenazine Tosylate | 12 | $85,920 |
| Aimovig AutoinjectorErenumab-Aooe | 84 | $61,632 |
| Nurtec OdtRimegepant Sulfate | 36 | $43,837 |
| Emgality PenGalcanezumab-Gnlm | 47 | $38,283 |
| Lacosamide | 380 | $36,691 |
| UbrelvyUbrogepant | 29 | $30,232 |
| QuliptaAtogepant | 17 | $29,762 |
| RytaryCarbidopa/Levodopa | 55 | $29,658 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 30 | $21,477 |
| VimpatLacosamide | 23 | $19,080 |
| Lamotrigine ErLamotrigine | 45 | $17,540 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SK Life Science, Inc.Xcopri | $194 | $307,598252 claims |
| UCB, Inc.Briviact, Vimpat | $236 | $110,92878 claims |
| Acadia Pharmaceuticals IncNuplazid | $40 | $93,89319 claims |
| AbbVieUbrelvy, Qulipta | $517 | $59,99446 claims |
| Amneal Pharmaceuticals LLCRytary | $31 | $29,65855 claims |
| Upsher-smith Laboratories LLCTopiramate | $21 | $4,114293 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,246 neurology providers in Texas.
Other neurology in Austin
- Esther MelamedAustin$593K
- Sami AboumatarAustin$593K
- Ann BassSan Antonio$12.3M
- Kandasami SenthilkumarBeaumont$7.6M
- Bharathy SundaramSherman$7.2M
- Bhupesh DiheniaLubbock$6.9M
- Jamshid LotfiHouston$6M
- Nazanin MajdHouston$5.9M
- Aziz ShaibaniHouston$5.5M
- Elizabeth PeckhamRound Rock$5.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.